BENEVOLENTAI overview

Regulatory News: BenevolentAI, (“BenevolentAI” or “the Company”) (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces that: All resolutions proposed at its Extraordinary General Meeting held today (the “EGM”) were duly passed with overwhelming support (over 95% in favour). Effective immediately, BenevolentAI has merged into Osaka Holdings S.à r.l. (“Osaka Holdings”). As a result, the original BenevolentAI entity has ceased to exist. Simultaneously,...

Regulatory News: BenevolentAI, (“BenevolentAI” or “the Company”) (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces: Subject to shareholder approval, the proposed delisting of BenevolentAI from Euronext Amsterdam N.V. (the “Delisting”) via a merger of the Company into Osaka Holdings S.à r.l. (“Osaka Holdings”), (the “Merger”), which will transition the Company to a private company structure. Simplification of the Company’s share structure and...

Regulatory News: BenevolentAI (“the Company”), a pioneer in integrating artificial intelligence with biopharmaceutical development, today unveils a major strategic overhaul to return the Company to its founding TechBio mission. These changes mark a return to the Company’s foundational strengths, refocusing efforts on core technologies and innovation to better develop transformative drug discovery and development solutions. In parallel, and to support this, the Company has initiated...

Regulatory News: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces that Dr. Jackie Hunter is retiring from the Board as a Non-Executive Director. Dr. Jackie Hunter has served on the Board of the Company since it listed in April 2022, having previously served on the board of BenevolentAI Limited since March 2016. Dr. François Nader, Chair of BenevolentAI, said: “The...

BenevolentAI ​​(Euronext Amsterdam: BAI), a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712. BEN-34712 is an oral, potent and selective brain penetrant RARɑβ (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies. Impaired retinoic acid signalling has...

BenevolentAI ​​(Euronext Amsterdam: BAI), a leader that combines cutting-edge Artificial Intelligence (AI) and science to accelerate biopharma discovery and development, announces that AstraZeneca presented new preclinical data on an AI-generated target identified in their ongoing collaboration with BenevolentAI. The data was presented at the ATS International Conference 2023. The research provides further scientific information on Serum Response Factor (SRF) as a potential target for...